Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.
We assign a fundamental rating of 8 out of 10 to NVO. NVO was compared to 198 industry peers in the Pharmaceuticals industry. NVO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: NVO is growing strongly while it also seems undervalued. With these ratings, NVO could be worth investigating further for value and growth and quality investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.68% | ||
ROE | 70.38% | ||
ROIC | 43.02% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 46.16% | ||
PM (TTM) | 34.78% | ||
GM | 84.67% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.62 | ||
Debt/FCF | 1.48 | ||
Altman-Z | 5.03 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.74 | ||
Quick Ratio | 0.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 17.37 | ||
Fwd PE | 14.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 25.1 | ||
EV/EBITDA | 11.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.71% |